Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain.
Crespo J, Diago M, Cabezas J, Berenguer M, Broquetas T, Serra MÁ, Morillas R, García-Samaniego J, Calleja JL, Sánchez JJ, Lens S, Soto-Fernández S, Sacristán B, Fernández I, López-Núñez C, Buti M, Romero-Gómez M, Sáez-Royuela F, Fernández C, Jorquera F, Sánchez-Antolín G, Pascasio JM, Cuadrado A, Hernández-Guerra M. Crespo J, et al. Ann Hepatol. 2015 Jul-Aug;14(4):477-86. Ann Hepatol. 2015. PMID: 26019034 Free article.
Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.
Diago M, Castellano G, García-Samaniego J, Pérez C, Fernández I, Romero M, Iacono OL, García-Monzón C. Diago M, et al. Gut. 2006 Mar;55(3):374-9. doi: 10.1136/gut.2005.074062. Epub 2005 Sep 8. Gut. 2006. PMID: 16150856 Free PMC article. Clinical Trial.
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.
Sánchez-Tapias JM, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R, Crespo J, Andrade R, Martínez-Bauer E, Pérez R, Testillano M, Planas R, Solá R, García-Bengoechea M, Garcia-Samaniego J, Muñoz-Sánchez M, Moreno-Otero R; TeraViC-4 Study Group. Sánchez-Tapias JM, et al. Gastroenterology. 2006 Aug;131(2):451-60. doi: 10.1053/j.gastro.2006.05.016. Gastroenterology. 2006. PMID: 16890599 Clinical Trial.
[Adefovir dipivoxil compassionate use program in Spain: efficacy and resistance analysis].
Buti M, Rodríguez Frías F, Calleja JL, Jardí R, Pons F, Crespo J, Casanovas T, Enríquez J, Carnicer F, Romero M, García Bengoechea M, Prieto M, García Samaniego J, Miras M, Pérez Roldán F, Rueda M, Esteban R. Buti M, et al. Med Clin (Barc). 2007 Oct 27;129(15):566-70. doi: 10.1157/13111710. Med Clin (Barc). 2007. PMID: 17988612 Clinical Trial. Spanish.
Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment.
Erhardt A, Deterding K, Benhamou Y, Reiser M, Forns X, Pol S, Calleja JL, Ross S, Spangenberg HC, Garcia-Samaniego J, Fuchs M, Enríquez J, Wiegand J, Stern J, Wu K, Kukolj G, Marquis M, Beaulieu P, Nehmiz G, Steffgen J; BILB 1941 Study Group. Erhardt A, et al. Antivir Ther. 2009;14(1):23-32. Antivir Ther. 2009. PMID: 19320234 Clinical Trial.
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin.
Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández-Rodríguez CM, Solà R, García-Samaniego J, Herrerías JM, De la Mata M, Moreno-Otero R, Nuñez O, Olveira A, Durán S, Planas R; Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Romero-Gómez M, et al. Hepatology. 2009 Dec;50(6):1702-8. doi: 10.1002/hep.23206. Hepatology. 2009. PMID: 19845037 Clinical Trial.
228 results